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Abstract 
Background and Objectives: Long-acting injectable (LAI) antiretrovirals (ARVs) represent a pharmacological 
alternative to oral formulations and an innovative clinical option to address adherence and reduce drug costs. 
Clinical studies in children and adolescents are characterised by ethical and logistic barriers complicating the 
identification of dose optimisation. Physiologically-based pharmacokinetic (PBPK) modelling represents a valu-
able tool to inform dose finding prior to clinical trials. The objective of this study was to simulate potential dos-
ing strategies for existing LAI depot formulations of cabotegravir and rilpivirine in children and adolescents (3-
18 years) using PBPK modelling. 
Methods: Whole-body PBPK models were developed to represent the anatomical, physiological, molecular 
processes and age related changes in children and adolescents through allometric equations. Models were vali-
dated for LAI intramuscular (IM) cabotegravir and rilpivirine in adults. Subsequently, the anatomy and physiol-
ogy of children and adolescents was validated against available literature. The optimal doses of monthly admini-
stration of cabotegravir and rilpivirine were identified in children and adolescents, in order to achieve trough 
concentrations over the target concentrations derived in a recent efficacy trial of the same formulations. 
Results: Pharmacokinetic data generated through the PBPK simulations were similar to observed clinical data 
in adults. Optimal doses of LAI ARVs cabotegravir and rilpivirine were predicted using the release rate ob-
served for existing clinical formulations, for different weight groups of children and adolescents. The IM load-
ing dose and maintenance dose of cabotegravir ranged from 200 – 600 mg and 100 – 250 mg respectively and 
for rilpivirine it ranged from 250 – 550 mg and 150 – 500 mg respectively across various weight groups of chil-
dren ranging from 15-70 kg. 
Conclusions: The reported findings represent a rational platform for the identification of suitable dosing strate-
gies and can inform prospective clinical investigation of LAI formulations in children and adolescents. 
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Key Points 
 Mathematical models defining anatomical, physiological and molecular processes were constructed to 
simulate drug pharmacokinetics in children and adolescents. 
 Two clinically available long-acting formulations of cabotegravir and rilpivirine were utilised to report 
minimum doses needed in paediatric individuals relative to their weight. 
 Evaluation of a mathematical model to identify minimum doses in children and adolescents represents 
an innovative method to inform dosing strategies in various kinds of population over a range of thera-
peutic areas.  
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1. Introduction 
HIV (Human Immunodeficiency Virus) is one of the leading causes of death that is treated as a global prior-
ity. Initiation of HAART (Highly Active AntiRetroviral Therapy) has saved millions of lives in the past decade 
[1]. However, adherence to antiretroviral therapy continues to be one of the major issues hindering treatment 
efficacy and suboptimal adherence can extremely vary in patients ranging from 50 to 70 % in the clinical setting 
[2]. Currently available formulations necessitate lifelong, daily dosing and poor adherence has been attributed to 
numerous factors including pill fatigue, side effects and a range of socioeconomic considerations associated 
with different populations [3]. Problems can be particularly exacerbated in specific sub-populations of patients 
such as paediatric patients, where drug administration is additionally influenced by the caregiver, the family or 
the social environment [4].   
Long acting injectable (LAI) formulations have the potential of solving the adherence issues related to oral 
formulations, reducing the amount of antiretroviral (ARV) used for the therapy and consequently the cost of 
therapy. The use of LAI formulations in paediatric patients has already been hypothesised in different disease 
areas and the use of LAI antipsychotics has been recently described in adolescents [5-7].  
Two LAI ARV formulations have recently been developed and several others are currently under investiga-
tion [1]. Rilpivirine and cabotegravir, due to long half-life and potency, have been selected for monthly and 
quarterly LA administration, respectively [1, 8].  Clinical studies investigating the combination of cabotegravir 
and rilpivirine LAI formulations are currently ongoing to assess its safety and efficacy in adults [9]. Recent 
clinical trials (LATTE and LATTE-2)  conducted in HIV infected adults show that cabotegravir and rilpivirine 
combination are safe and efficacious which provide similar antiviral activity as efavirenz plus NRTIs – tenofovir 
and emtricitabine [10]. The combination of rilpivirine and cabotegravir has the potential of being the first long-
acting antiretroviral regimen that will not require daily oral dose of any companion drugs, representing a pivotal 
achievement in the antiretroviral pharmacology. However, the identification of safe and effective dosing strate-
gies for paediatric patients is complicated by multiple factors. Differences in anatomical and physiological char-
acteristics of children and adolescents compared to adults have a relevant effect on ADME processes and are not 
correctly captured through traditional allometric scaling approaches [11]. Additionally, logistic and ethical chal-
lenges in designing dose finding/optimisation studies have limited medical guidance [12].  
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Physiologically based pharmacokinetic (PBPK) modelling represents a valuable tool to optimise doses prior 
to clinical trials in paediatric patients thus minimising the time and cost invested in optimising doses. PBPK 
modelling is the mathematical description of anatomical, physiological and molecular processes defining phar-
macokinetics. Compared to techniques usually used to select paediatric doses of adult formulations [13-16], 
PBPK modelling is a bottom up approach which integrates in vitro data such as apparent intestinal permeability, 
intrinsic clearance, protein binding, etc. in a mathematical description of ADME to predict in vivo pharmacoki-
netics [17].  
Previous studies identified trough concentration of 1.2 µg/ml and 17 ng/ml for cabotegravir and rilpivirine 
respectively need to be achieved to warrant efficacy [18, 19]. No toxicity limited concentrations has been re-
ported previously [1]. Therefore, the aim of this study was to simulate pharmacokinetics and inform optimal 
doses of LAI intramuscular (IM) formulations of cabotegravir and rilpivirine in at 95 % of children and adoles-
cents aged 3 to 18 years through PBPK modelling for HIV treatment.   
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2. Methods 
The PBPK models were constructed using Simbiology® v.4.3.1, a product of Matlab® v.8.2 (MathWorks, 
Natick, MA, USA 2013). Instant and uniform distribution of drugs into tissues, no reabsorption of the drug from 
the large intestine and a blood-flow limited model [20] were assumed. A previously published adult IM PBPK 
model was used in this study [21]. Cabotegravir and rilpivirine LAI IM pharmacokinetics were simulated and 
validated in adult PBPK models and later optimised for different weight categories of children (3-12 years) and 
adolescents (12-18 years). Children and adolescents between the ages 3-18 years were divided into WHO 
weight groups [22] and 100 virtual individuals were generated in each weight category. 
2.1 Anatomy 
Adult PBPK models were defined by key characteristics such as age and weight of the individual. These de-
fining characteristic values were further used for the computation of organ and tissue volumes, as well as blood 
flow rates through allometric equations described by Bosgra et al. [23]. The anatomy and physiology of children 
and adolescents were obtained from various literature sources, validated against available clinical data prior to 
dose optimisation [23-33]. To improve the confidence of the constructed paediatric PBPK models, validation 
against intravenous lorazepam and intramuscular ceforanide as reference drugs was also conducted [34]. The 
various equations used for the construction of paediatric PBPK models and validation across different ages are 
available in Online Resource 1.  
2.2 Simulation of ADME processes 
Drug diffusion from the IM compartment was assumed to obey first order rate kinetics and the equation was 
obtained from Tegenge et al.[35]. The release rate of cabotegravir was obtained from the literature [36] and for 
rilpivirine, was derived using 48-week clinical data from LATTE-2, a recent Phase 2 efficacy trial of these two 
formulations used in combination [19]. The intrinsic clearance values derived from in vitro data were obtained 
from the literature [37] and extrapolated to systemic clearance [38]. The distribution of drug to different organs 
and tissues was simulated using previously published equations [21]. 
2.3 Model validation  
The physicochemical properties of cabotegravir and rilpivirine used in the model are presented in Table 1. 
The validation of the drug properties against clinical data was conducted in 100 virtual adults for a 800 mg quar-
terly dose of cabotegravir (from weeks 12-28) and for a subsequent monthly dose of 900 mg rilpivirine (after the 
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initial dose of 1200 mg) [1]. The release rate of rilpivirine was identified from the clinical data using the PBPK 
model [1]. The release rate was also validated against the LATTE-2 pharmacokinetic curve of cabotegravir and 
rilpivirine. The cabotegravir release rate was assumed to be 4.54  10-4 h-1 to be same as in LATTE-2 (or prior 
adult studies); however there was a decrease in the release rate of rilpivirine from  9  10-4  to 5   10-4 h-1,  since 
the rilpivirine formulation included in LATTE-2 was different from previous investigation and  [19] with a 
slower release rate [1]. A schematic of the LATTE-2 dosing regimen implemented in this study is shown in Fig 
2. 
2.4 Dose prediction 
After the validation of the physicochemical parameters, the anatomy and physiology were modified to de-
scribe children and adolescents using appropriate allometric equations obtained from the literature, as described 
in the Online Resource 1  [12, 23, 25-27, 39, 40]. Following IM injection, dose optimisation in healthy paediat-
ric individuals was conducted such that at least 95 out of the 100 virtual individuals had a mean trough concen-
tration (Ctrough) over the target trough concentrations for the required duration. Based on the LATTE-2 study, a 
target Ctrough of 1.35 µg/ml was used as the minimum target trough concentration for cabotegravir dose predic-
tions following 10 mg oral dose, and 70 ng/ml was used as the average concentration (Cav) for rilpivirine follow-
ing a 25 mg dose [19]. An oral dosing regimen for 4 weeks (steady state) followed by a loading dose and eleven 
maintenance doses for a 4-weekly IM administration of rilpivirine and cabotegravir were simulated, for a total 
period of 52 weeks. 
2.5 Sensitivity analysis 
A differential sensitivity analysis was performed to identify the key parameters that impact the pharmacoki-
netic profiles of LA formulations [41]. Analysis was performed for the loading dose and the first maintenance 
dose of cabotegravir and rilpivirine LAI IM formulation in adults. Sensitivity was analysed using the provided 
inbuilt feature of Simbiology at user-defined values without normalisation in the computation. Six parameters –
blood-to-plasma ratio, cardiac output, plasma clearance, liver weight, fraction unbound and release rate were 
analysed against drug plasma concentrations. Each parameter was varied by 20% from its mean value and 100 
simulations were conducted while keeping the rest of the parameters constant. The sensitivity coefficient (ϕi) 
indicates the change of plasma concentration values (Y) with respect to a unit change in a parameter (X) as 
shown in equation 1 [41].  
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3. Results 1 
The structure and equation of the current PBPK model are based on a previous publication and modified to 2 
represent antiretroviral distribution in paediatric and adolescent individuals  [21]. The anatomy and physiology 3 
of children and adolescents was also validated against literature and the results are presented in Online Re-4 
sources 1. PBPK models were initially qualified by validation against available clinical data for both cabo-5 
tegravir and rilpivirine in adults to ensure that the selected drug properties were appropriate. The mean simu-6 
lated pharmacokinetic parameters for maximum concentration (Cmax), Ctrough and area under the concentration-7 
time curve (AUC) were compared against available clinical data for the LA formulations for both drugs used in 8 
adults (cabotegravir – second IM dose of 800 mg and rilpivirine – 900 mg after the initial dose of 1200 mg) 9 
(shown in Table 2 and Fig. 1).  A stringent qualification of accuracy was applied whereby PBPK models were 10 
considered validated only if the mean value was within 0.5-fold from the clinical value, rather than the conven-11 
tional 2-fold agreement limits [42].  12 
The formulation characteristics were maintained equal to the adult formulation for the simulations in chil-13 
dren and adolescents assuming a similar release rate of the drugs from the formulations, and the use of the same 14 
formulations in adult, children and adolescents.  IM doses were optimised to have a pharmacokinetic profile 15 
with concentration exceeding the 10 mg PO Ctrough for cabotegravir over the duration of treatment and an aver-16 
age concentration over the Ctrough of 25 mg PO rilpivirine for the first 12 IM doses (Fig. 3). For rilpivirine, it was 17 
also ensured that the concentrations were always above the 90% protein binding adjusted inhibitory concentra-18 
tion (PAIC90) value of 12.1 ng/ml [18] subsequent to the loading dose. Summary of predicted doses for both 19 
cabotegravir and rilpivirine for different weight categories are shown in Table 3. 20 
3.1 Cabotegravir 21 
The validation for 800 mg IM cabotegravir resulted in mean predicted AUC, Cmax and Ctrough values that 22 
were +15.6 %, +6.1 % and +9.1 % compared to  clinical values, respectively [1]. A target trough concentration 23 
of 1.35 µg/ml (10 mg PO Ctrough) was chosen from the literature [1]. The doses for different weight groups were 24 
informed such that at least 95 out of the 100 virtual individuals had a Ctrough value over the target trough concen-25 
tration for a duration of 48 weeks (Fig 4). The daily oral dose administered for a period of 4 weeks was 10 mg 26 
for weights ranging between 14-50 kg and 20 mg for weights between 50-70 kg. For IM cabotegravir, the load-27 
ing dose ranged between 200-600 mg and maintenance doses between 100-250 mg for the simulated plasma 28 
Ctrough to stay over the 10 mg PO Ctrough as described in Table 3.  29 
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3.2 Rilpivirine 30 
The simulated mean AUC, Cmax and Ctrough values were +13.2 %, -6.5 % and -8.8 %, compared to the clini-31 
cal data [1]. After the validation of rilpivirine PBPK model, the first order kinetic release rate was identified to 32 
be  9   10-4 h-1 [1]. The validation was then performed to find the optimal release rate for rilpivirine pharma-33 
cokinetics from the LATTE-2 study. Due to reformulation of the rilpivirine, the optimal release rate was ob-34 
served to be 5   10-4 h-1. The optimal doses were informed for different weight categories such that the average 35 
drug Ctrough plasma concentrations of 48 weeks remained over 70 ng/ml (25 mg PO Ctrough) [19]. A fixed daily 36 
oral dose of 25 mg was administered for 4 weeks prior to IM doses. The loading dose ranged from 250 – 550 mg 37 
and the maintenance doses from 200 – 500 mg across weight groups from 15-70 kg individuals. The optimal 38 
doses ensured plasma concentrations over the PAIC90 value and average IM concentrations over 25 mg PO 39 
Ctrough for at least 95 out of 100 individuals (Fig 5).  40 
3.3 Sensitivity Analysis 41 
Fig. 6 shows the mean differential sensitivity analysis plot of 100 runs for six chosen parameters with re-42 
spect to time. The analysis was performed for two successive (loading and maintenance) monthly IM doses of 43 
cabotegravir and rilpivirine in adults.  44 
For cabotegravir, the analysis indicated that the plasma concentration is sensitive to only two of the six fac-45 
tors and higher influence was observed in the first days following administration. Cardiac output and systemic 46 
clearance of drug had higher sensitivity towards the variation in plasma concentrations. Protein binding, release 47 
rate, liver weight and blood-to-plasma ratio were negligibly sensitive. This indicates that physiological factors 48 
and the UGT content in the liver had a higher potential to influence the simulated pharmacokinetics.  Sensitivity 49 
against cardiac output was negative for most of the duration indicating an increased effect against plasma con-50 
centration even when the value changes by ± 20% from the mean. Sensitivity against systemic clearance had a 51 
similar trend to cardiac output but with lower intensity. During the initial days after the administration of the 52 
maintenance dose, both these factors showed a positive relationship against plasma concentration indicating a 53 
lower effect.  54 
For rilpivirine, the change in plasma concentration was not sensitive when cardiac output, liver weight and 55 
release rate varied ± 20 % from the mean. Blood-to-plasma ratio had a higher positive effect immediately after 56 
dosing implying a lower influence on plasma concentration. Blood-to-plasma ratio and systemic clearance 57 
showed a positive relationship over the entire dosing period indicating a decreased effect against plasma concen-58 
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tration. Protein binding fluctuated between positive and negative, however the variation is minimal signifying 59 
minimal or no effect on plasma concentration.   60 
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4. Discussion 61 
Optimal treatment adherence is essential for effective inhibition of viral replication and to mitigate devel-62 
opment of resistance to ARVs. Although oral formulations have been demonstrated to result in therapeutic con-63 
centrations, sub-optimal adherence in patients who are receiving oral daily dosing for treatment and prevention 64 
have been described [2, 43-46]. Alternative administration strategies could support higher adherence reducing 65 
the frequency of administration and addressing pill fatigue. More specifically, formulations allowing a monthly 66 
or quarterly administration could address the adherence issue, thus decreasing the risk of drug resistance. ARVs 67 
with high potency and favourable pharmacokinetics are essential for the development of the LAI strategy. The 68 
recent development of novel formulations of cabotegravir and rilpivirine constitute a remarkable step towards 69 
the definition of LAI strategies, providing innovative pharmacological tools for adults [1]. Dose optimisation in 70 
special populations of patients such as children and adolescents is complex due to their unique physiological and 71 
anatomical characteristics compared to adults. Traditionally, clinical trials have not been frequently conducted 72 
in these patient populations due to ethical and logistical considerations [47]. However recent regulations pro-73 
mote clinical studies in paediatric patients to evaluate safety and efficacy prior to therapy [48, 49]. The present 74 
study focuses on the identification of dosing strategies of cabotegravir and rilpivirine in children and adolescents 75 
using computational PK modelling for HIV treatment.  76 
Various PBPK models have been developed for adults and recently this modelling technique has also been 77 
used for a variety of special populations including children and adolescents [50, 51]. Drug distribution can be 78 
simulated in special populations of patients through the integration of age-related anatomical and physiological 79 
changes into the mathematical PBPK framework. PBPK modelling has been recently used for the prediction of 80 
midazolam and theophylline in neonates, infants and children [12]. In two other studies, the relationship be-81 
tween adult and paediatric clearance rates was established using cytochrome P450 ontogeny for six compounds 82 
and then simulations were performed for five different drugs at different age groups [52, 53]. An oseltamivir 83 
PBPK model was used to predict pharmacokinetics in neonates and infants with influenza [54] and a disease-84 
specific model was also recently developed in children with and without liver cirrhosis [55]. 85 
Both cabotegravir and rilpivirine are characterised by long-half lives and physicochemical properties that 86 
are compatible with nanoformulations for LAIs, represent attractive options for continuous therapy [1, 56]. Us-87 
ing physiochemical properties and in vitro data, the pharmacokinetics of cabotegravir and rilpivirine in adults 88 
was validated against available clinical data. The model validation was conducted at the second dose of the LAI 89 
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ARVs to have a mathematical representation of the pharmacokinetics at steady-state. Low accuracy and preci-90 
sion was observed in the ÉCLAIR study where the simulated Ctrough value of cabotegravir was 1.35 µg/ml com-91 
pared to the observed value which was less than 0.66 µg/ml (4*PAIC90)[57]. Hence, stringent guidelines were 92 
applied for the validation process where ± 50 % deviation from the mean clinical values was considered accept-93 
able instead of the conventional 2-fold deviation [42]. The pharmacokinetic parameters – AUC, Cmax and Ctrough 94 
simulated through the PBPK approach were in agreement with the clinical data and therefore our PBPK model 95 
was considered robust for predicting the LAI IM doses in children and adolescents. In the simulation of LAI 96 
pharmacokinetics in children, the release rates of the LAI formulations were maintained equal to the validation 97 
in adults, to facilitate bridging to paediatric simulation. Although the physiology of the muscular tissues is dif-98 
ferent between adults and children, this could potentially support the use of the existing formulations in paediat-99 
ric clinical studies with no further reformulation [58]. However additional studies are required since there is a 100 
possibility that smaller doses with less injection volume could decrease total surface area and strain in the mus-101 
cle, thereby altering the pharmacokinetic profile. The doses were optimised such that cabotegravir and ril-102 
pivirine concentrations were over the target trough concentrations (described in methods section) for the dura-103 
tion of the dose. Although PAIC90 values indicate a trough concentration to suppress the virus in vitro, this does 104 
not translate in effective therapeutic activity in vivo [59]. Therefore, the dose optimisation was conducted con-105 
sidering LATTE-2 study target trough concentrations. 106 
The required dose was proportional to the weight of the individual which indicates increase in volume of 107 
distribution and systemic clearance in adolescents. As the weight of the individual increased from 15 to 70 kg, 108 
the required dose of cabotegravir tripled in an individual weighing 70 kg compared to a 15 kg individual 109 
whereas the dose needed was just over double in the case of rilpivirine. Fluctuation in maximum and trough 110 
plasma concentration of cabotegravir is >2 µg/ml compared to rilpivirine (<100 ng/ml). Also cabotegravir is 111 
more sensitive to variations in clearance and cardiac output compared to rilpivirine (as shown in Fig. 6) and due 112 
to these physiological variations across weight groups, higher dose is required in case of cabotegravir for ado-113 
lescents compared to children. This indicates that doses cannot be linearly extrapolated based on weight and a 114 
deeper understanding of important mechanistic processes influencing the pharmacokinetics in children and ado-115 
lescents is required. The loading doses are higher compared to the maintenance doses as the extra dose is essen-116 
tial to maintain drug plasma concentrations over the Ctrough/PAIC90 values. Since the maintenance dose for cabo-117 
tegravir is low compared to rilpivirine, they could be more suitable for a less frequent (bimonthly or quarterly) 118 
administration. 119 
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LAI formulations may improve the problems faced with low adherence of therapies in children and adoles-120 
cents. The identification of optimal doses in healthy paediatric individuals should be given priority as most of 121 
the doses for prescribed drugs are simply scaled from adult doses with varying success. However pain involved 122 
during the administration of IM injections has the potential to refrain children from preferring this route and 123 
opting for oral dosing regimens. Chloramphenicol dose scaling from adults in neonates and infants reached toxic 124 
levels which led to higher mortality rate, an example where the developmental pharmacology of paediatric pa-125 
tients was ignored [60]. Mortality rate was high in neonates affected with kernicterus who were administered 126 
penicillin/sulfisoxazole than with oxytetracycline in an another case [61]. In both these cases, an immature glu-127 
curonidation system led to the accumulation of drug, resulting in high plasma concentrations and conclusively 128 
demonstrating that the physiological processes of the child cannot always be accounted for by scaling adult 129 
doses [61, 62]. 130 
Although the simulated doses for children and adolescents could represent a valuable guideline for drug 131 
safety and efficacy clinical studies, the applied modelling strategies have some limitations. Numerous barriers 132 
can complicate the implementation of dosing recommendations for special populations. Since anatomical and 133 
physiological changes in children follow non-linear trend, pharmacokinetic, pharmacodynamic investigations 134 
need to be conducted to evaluate the safety, efficacy and tolerability profiles in children and the current model-135 
ling approach can support a rational identification of suitable dosing strategies [63]. Especially in infants and 136 
neonates younger than three years, ontogeny of CYP450 expression in the liver and wide variation in organ 137 
weights and volumes could lead to low accuracy in model prediction and hence this study focuses on children 138 
older than three years. Some anatomical and physiological features and the associated complex biological proc-139 
esses have not been simulated due to a paucity of relevant data [35]. Absence of information on drug transport-140 
ers at the injection site could alter the absorption, distribution and metabolic processes which could not be cap-141 
tured in the current PBPK model. Evidence suggests that cabotegravir undergoes enterohepatic recirculation, 142 
however quantitative evaluation of this physiological process is absent and hence could not be incorporated in 143 
the PBPK model [64]. Recent investigation with paliperidone LAI micro suspension revealed formation of a 144 
granuloma due to macrophage accumulation surrounding the site of injection. This phenomenon further con-145 
trolled drug release from the depot and evidence also showed drug uptake and release from macrophages [65]. 146 
The extent of the occurrence of this phenomenon and the size of the depot could alter the release rates and 147 
thereby drug pharmacokinetics which was not accounted for in this study. Physiological and metabolic variation 148 
of muscle composition in children compared to adults was not accounted during the dose optimisation process 149 
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[58]. Low clinical Cmax compared to the simulated pharmacokinetic curve (Fig. 1) could be due to the fraction of 150 
drug distributed through the lymphatic circulation. Additionally, the potential adverse effects considering the 151 
differences in the anatomy and physiology of children compared to adults, prolonged exposure and inability to 152 
discontinue therapy once administered are important factors to be assessed before drug administration [3].  153 
LAI therapy has attracted a great deal of attention in various therapeutic areas, including chronic HIV infec-154 
tion. For example, the National Institutes of Health (NIH) recently provided support to set up a worldwide team 155 
involving researchers from academia and the pharmaceutical industry to facilitate development of LAI formula-156 
tions for HIV. This Long-Acting/Extended Release Antiretroviral Resource Program (LEAP; 157 
www.longactinghiv.org) includes a PBPK modelling service to facilitate the design of long-acting formulations 158 
for HIV and related infectious diseases.  This kind of support may improve the efficiency of selection of formu-159 
lations, doses, and dose intervals for paediatric and other special populations.  160 
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5. Conclusion 161 
PBPK models were successfully validated for both cabotegravir and rilpivirine LAI formulations against 162 
available clinical data in adults. A novel PBPK model for the prediction of PK in children and adolescent indi-163 
viduals was developed to simulate dose selection in this vulnerable group. Dosing strategies for cabotegravir 164 
and rilpivirine were estimated in different weight groups of children and adolescents considering two efficacy 165 
target trough concentrations. From this modelling study, the predicted paediatric dosing of caboteravir and 166 
rilpivirine differ for each weight category and scaling adult dose could have led to plasma concentration either 167 
below PAIC90/MEC value or above safe level. Different dosing fractions compared to adult dosages for 168 
cabotegravir and rilpivirine indicate that drug specific physiocochemical parameters and ADME characteristics 169 
play a key role in controlling pharmacokinetics. PBPK predictions from this study could potentially inform 170 
reference doses required to conduct paediatric clinical trials for various weight categories.  171 
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6. Tables 188 
Table 1 Physicochemical properties, in vitro and population pharmacokinetic data of ARVs  189 
  Cabotegravir Rilpivirine 
Molecular weight 427 366 
log Po:w 1.04 [66] 4.32 [67] 
Protein binding 99.30% [56] 99.70% [67] 
pKa 10.04 [66] 3.26 [67] 
R 0.441 [68] 0.67 [67] 
Polar surface area 99.2 - 
Hydrogen bond donors 2 - 
Caco-2 permeability (cm/s) - 12 × 10
-6 [67] 
CYP3A4 CLint - 2.04 [67] 
UGT1A1 CLint  4.5 [37] - 
UGT1A9 CLint 2.2 [37] - 
Release rate (h
-1
) 4.5   10-4  [36] 9   10-4  [1] 
log Po:w – Partition coefficient between octanol and water; pKa – logarithmic value of the dissociation constant; 190 
R – blood-to-plasma drug ratio; CLint – intrinsic clearance; CYP – cytochrome P450 (µl/min/pmol); UGT - 191 
uridine diphosphate glucuronosyltransferase (µl/min/mg)  192 
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Table 2 Validation of cabotegravir and rilpivirine after the second IM dose in adults: Clinical [1] vs. simulated 193 
pharmacokinetic data 194 
Drug Dose 
(mg) 
AUC  Cmax Ctrough 
Clinical Predicted Clinical Predicted Clinical Predicted 
Cabotegravir 800 mg 
quarterly 
4467 (52)  5166 (23) 3.3 (59) 3.5 (21) 1.1 (140) 1.2 (24) 
Rilpivirine 900 mg 
monthly 
74,420 
(35) 
84,270 (44) 168 (37) 157 (42) 79.1 (44) 72.1 (45) 
Values are represented as Geometric mean (% CV – coefficient of variation expressed as a percentage), AUC – 195 
area under the concentration-time curve, Cmax – maximum plasma concentration, Ctrough – trough plasma concen-196 
tration. For Cabotegravir Cmax and Ctrough are µg/ml and AUC is µg × h/ml at day 84. For rilpivirine Cmax and 197 
Ctrough are ng/ml and AUC is ng × h/ml at day 28  198 
20 
 
Table 3 Prediction of the dose (in mg) for cabotegravir and rilpivirine for different weight categories of children 199 
and adolescents with initial 4 weeks of oral dose followed by IM loading dose and 11 maintenance doses lasting 200 
4-weeks each 201 
Weight (kg) Rilpivirine Cabotegravir 
 Oral 
Loading 
dose 
Maintenance 
dose 
Oral Loading dose 
Maintenance 
dose 
14 - 19.9 
25 
250 150 
10 
200 100 
20 - 24.9 250 200 250 100 
25 - 29.9 250 200 250 100 
30 - 34.9 300 250 350 150 
35 - 39.9 350 300 350 150 
40 - 44.9 400 300 400 150 
45 - 49.9 450 350 450 150 
50 - 54.9 450 400 
20 
450 200 
55 - 59.9 500 400 500 200 
60 - 64.9 500 450 550 200 
65 - 69.9 550 500 600 250 
Target  
concentration in ng/ml 
(achieved by a PO 
dose in mg) [Refer-
ence] 
70 (25 mg PO Ctrough) [19] 1370 (10 mg PO Ctrough ) [19] 
PO – oral route, Ctrough – trough concentration  202 
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Figure Legends 386 
Figure 1 Validation of the PBPK model parameters against clinical data for the second IM administration in 387 
adults. a) Cabotegravir (800 mg followed by 800 mg quarterly) b) Rilpivirine (1200 mg followed by 900 mg 388 
monthly) [1] 389 
Figure 2 Validation of adult PBPK model using LATTE-2 dosing regimen. Oral dosing regimen was followed 390 
for 4 weeks, followed by a single 4-weekly intramuscular dose and eleven 4-weekly intramuscular maintenance 391 
doses. CAB – cabotegravir, RPV – rilpivirine, QD – once daily, Q4W – 4-weekly dose 392 
Figure 3 Validation of the release rate against clinical data from 48-week LATTE-2 study in adults. a) Cabo-393 
tegravir b) Rilpivirine [19]. The target trough concentration is 1.35 µg/ml for cabotegravir and 12 ng/ml for ril-394 
pivirine 395 
Figure 4 Plasma concentrations of cabotegravir loading and maintenance doses from week 4 to week 52 for 396 
different weight categories of children and adolescents. a) 14 - 19.9 kg, b) 25 - 29.9 kg, c) 35 - 39.9 kg, d) 45 - 397 
49.9 kg, e) 55 - 59.9 kg and f) 65 - 69.9 kg. The mean plasma concentrations are over the target trough concen-398 
trations of 1.37 µg/ml. Concentration data were derived from optimized dosing strategies calculated for each 399 
weight band, as described in the Results section. 400 
Figure 5 Plasma concentrations of rilpivirine loading and maintenance doses from week 4 to week 52 for differ-401 
ent weight categories of children and adolescents. a) 14 - 19.9 kg, b) 25 - 29.9 kg, c) 35 - 39.9 kg, d) 45 - 49.9 402 
kg, e) 55 - 59.9 kg and f) 65 - 69.9 kg. The mean plasma concentrations are over the target trough concentrations 403 
of 17 ng/ml. Concentration data were derived from optimized dosing strategies calculated for each weight band, 404 
as described in the Results section. 405 
Figure 6 Differential sensitivity analysis of plasma concentration against key parameters (blood-plasma ratio, 406 
cardiac output, fraction unbound, liver weight, release rate and systemic clearance) in adults for the 4-weekly 407 
intramuscular loading dose and the first maintenance dose. a) Cabotegravir, b) Rilpivirine408 
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Caption: PBPK model development and validation for paediatrics  17 
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1. Methods 19 
Anatomy and physiology of children between the ages 2-18 years were validated. The simulated 20 
pharmacokinetics were validated against published clinical data for lorazepam, an anti-anxiety agent and 21 
ceforanide, an anti-bacterial agent as model drugs [1, 2]. The physicochemical and drug specific parameters values 22 
were identified using standardised terminology. For the reported drugs, only a single value for each parameter 23 
could be identified.  24 
1.1 Anatomy 25 
The weight and body mass index of the individuals were defined using CDC growth charts. The charts were 26 
digitalised using plot digitizer tool and polynomial trend line feature in Microsoft excel was used to obtain the 27 
relation between age and other parameters [3].  Using these defined parameters as reference, height and body 28 
surface area [4] were calculated using allometric equations from the literature (Table 1). 29 
1.2 Tissue and organ weights 30 
The tissue and organ weights were computed using allometric equations. All the organ weights were validated 31 
against published data for both male and female populations at different age groups [5]. Summary of the equations 32 
used and their references are shown in Table 2a, 2b. 33 
1.3 Blood flow 34 
The cardiac output for different age groups was obtained from literature sources. The blood flow rates of 35 
various organs and tissues were adjusted as the percentage of cardiac output such that they match the clinical 36 
values [6]. The sum of blood flow passing through the gut, pancreas, spleen and stomach was considered as the 37 
portal vein blood flow rate for PBPK models. The blood flows were adjusted due to the unavailability of data in 38 
the literature (Table 3). 39 
1.4 Validation of anatomy and physiology 40 
The paediatric characteristics, individual tissue and organ weights and blood flows were validated against 41 
available literature data [5, 6]. Simulations were performed for a population (100 individuals) by including 42 
standard deviation from the literature or ± 20% was assumed if not available, in each age group and the mean 43 
value was validated against literature data for both male and female groups.  44 
  
1.5 Pharmacokinetic validation  45 
To improve the confidence of the constructed models, it was validated against lorazepam, an anti-anxiety 46 
drug [1]. This drug was chosen due to the availability of physicochemical and pharmacokinetic data required for 47 
the construction and validation of the PBPK model. Dose of 0.05 mg/kg to a maximum of 2 mg was administered 48 
intravenously and the pharmacokinetics were simulated for 100 male individuals in each age group. The PBPK 49 
model was also validated against a single intramuscular 20 mg/kg dose of an anti-bacterial agent, ceforanide [2]. 50 
Maximum concentration (Cmax), area under the curve (AUC) and volume of distribution (Vd) were compared 51 
against clinical data [1, 2]. 52 
1.6 ADME characteristics 53 
The equations describing the ADME processes defining PK were derived from previously published PBPK 54 
models [7, 8]. The physicochemical and intrinsic clearance values of lorazepam were obtained from Maharaj et 55 
al. [9] and the extrapolation to systemic clearance and the distribution of drug to different organs and tissues was 56 
computed using previously published equations [7, 10]. 57 
  
Table 1 Equations describing the anatomical characteristic features for paediatrics   58 
  Sex 2-7 years 7-18 years 
BMI 
Male 
(-2E-06*(Age*12)^3+0.0009*(Age*12)^2-0.096*(Age*12)+18.41) ± (4E-09*(Age*12)^4-3E-
06*(Age*12)^3+0.0006*(Age*12)^2-0.0421*(Age*12)+1.9366) [3] 
(0.004*Age^2+0.5348*Age+10.92) 
± 3 [3] 
Female 
(-2E-06*Age^3 + 0.0011*Age^2 - 0.1058*Age + 18.249)±(7E-09*Age^4 - 4E-06*Age^3 + 
0.0009*Age^2 - 0.0579*Age + 2.2788) [3] 
(-0.0204*Age^2 + 1.1067*Age + 
7.7386) ± 3 [3] 
Weight 
Male 
(-1E-07*(Age*12)^4+4E-05*(Age*12)^3-0.0052*(Age*12)^2+0.4118*(Age*12)+4.6681) ± (3E-
10*(Age*12)^5-2E-07*(Age*12)^4+5E-05*(Age*12)^3-0.0051*(Age*12)^2+0.2379*(Age*12)-2.3971) 
[3] 
(-0.0419*Age^3+1.684*Age^2-
17.334*Age+78.678) ± 4.5 [3] 
Female 
(-9E-09Age4 - 6E-06Age3 + 0.003Age2 - 0.1028Age + 13.926) ± (4E-10Age5 - 3E-07Age4 + 5E-05Age3 - 
0.0045Age2 + 0.1886Age - 1.4623) [3] 
(-0.239*Age2 + 9.6465*Age - 
39.288) ± 4.5 [3] 
BSA Both 0.0235*((Height*100)^0.42246)*(Weight^0.51456) [4] 
Height Both sqrt(Weight/BMI) 
 59 
  60 
  
Table 2 a) Allometric equations describing organ and tissue weights for male children between 2-18 years 61 
  2-7 years 7-18 years 
Adipose 0.534*Weight-1.59*Age+3.03 ± 0.041 [11] (1.51*BMI-0.7*Age-3.6*Sex+1.4)*Weight/100 ± 0.041 (Sex=0 for female, 1 for male) [12] 
Blood 
(-0.0623*(Age^5)+2.4425*(Age^4)-31.37*(Age^3) 
+149.98*(Age^2) +31.305*Age+393.7)/1000 ± 0.15 [13] (3.33*BSA-0.81) ± 0.1 [12] 
Bones 
(-0.0306*(Age^5)+0.5222*(Age^4)+9.7109*(Age^3)-
197.97*(Age^2)+1089.7*Age+546.6)/1000 ± 0.15 [13] exp(0.0689+2.67*log(Height)) ± 0.166 [11] 
Brain (0.405*exp(-Age/629)*(3.68-2.68*exp(-Age/0.89)) ± 0.084 [12] 
Glands (0.001*(Age^5)-0.0483*(Age^4)+0.8335*(Age^3)-6.6516*(Age^2)+27.512*Age+13.9 ± 0.015)/1000 [13] 
Gonads (3.3+53*(1-abs(exp((-Age/17.5)^5.4)))/1000 ± exp(0.049) [12] 
Heart (41.70+0.022*Age*365  ± 25)/1000 [14] 
Intestines (-4.7817e-2*(Age^4)+1.925*(Age^3)-22.382*(Age^2)+107.09*Age+51.125)/1000 ± 0.05 [13] 
Kidneys (35.29+0.015*Age*365+34.14+0.015*Age*365)/1000 ± 2.5 [14] 
Liver (271.58+0.163*Age*365 ± 25)/1000 [14] 
Lungs (41.31+0.039*Age*365+36.92+0.037*Age*365 ± 5)/1000 [14] 
Muscle 0.93*Weight-(Sum of organ weights) [12] 
Remaining exp(-0.072+1.95*log(Height) ± 0.049) [12] 
Skin exp(1.64*BSA-1.93) ± 0.049 [12] 
(-0.0992*(Age^4)+4.2762*(Age^3)-62.165*(Age^2)+437.78*Age+203.2)/1000 ± 0.2*(-
0.0992*(Age^4)+4.2762*(Age^3)-62.165*(Age^2)+437.78*Age+203.2)/1000 [15] 
Spleen (18.42+0.018*Age*365 ± 2.5)/1000 [14] 
Stomach exp(-3.266+2.45*log(Height) ± 0.0965) [12] 
Thymus (14*((7.1-6.1*exp(-Age/11.9))*((0.14+0.86*exp(-Age/10.3))))/1000 ± 0.049 [12] 
 62 
  63 
  
b) Allometric equations describing organ and tissue weights for female children between 2-18 years 64 
  2-7 years 7-18 years 
Adipose 0.642*Weight-0.12*Height-0.606*Age+8.98 ± 0.041 [11] (1.51*BMI-0.7*Age+1.4)*Weight/100 ± 0.041 [12] 
Blood 
(0.0018*(Age^5)+0.0959*(Age^4)-4.4055*(Age^3)+ 
44.442*(Age^2)+82.808*Age+292.26)/1000 ± 0.15 [13] (2.66*BSA-0.46) ± 0.1 [12] 
Bones 
(-2.831e-3*(Age^5)-0.18184*(Age^4)+10.685*(Age^3)-
142.88*(Age^2)+782.05*Age+609.64)/1000 ± 0.15 [13] exp(0.0689+2.67*log(Height)) ± 0.166 [11] 
Brain (0.373*exp(-Age/629)*(3.68-2.68*exp(-Age/0.89)) ± 0.084 [11] 
Glands (0.001*(Age^5)-0.0483*(Age^4)+0.8335*(Age^3)-6.6516*(Age^2)+27.512*Age+13.9 ± 0.015)/1000 [13] 
Gonads (3.3+90*(1-abs(exp((-Age/16.8)^6.7)))/1000 ± exp(0.049) [12] 
Heart (41.70+0.022*Age*365  ± 25)/1000 [14] 
Intestines (-0.0513*(Age^4)+2.0352*(Age^3)-23.478*(Age^2)+110.61*Age+49.229)/1000 ± 0.05 [13] 
Kidneys (35.29+0.015*Age*365+34.14+0.015*Age*365)/1000 ± 2.5 [14] 
Liver (271.58+0.163*Age*365 ± 25)/1000 [14] 
Lungs (41.31+0.039*Age*365+36.92+0.037*Age*365 ± 5)/1000 [14] 
Muscle 0.93*Weight-(Sum of organ weights) [12] 
Remaining exp(-0.072+1.95*log(Height) ± 0.049) [12] 
Skin exp(1.64*BSA-1.93) ± 0.049 [12] 
(0.00476622*(Age^5)-0.27924*(Age^4)+6.3444*(Age^3)-
70.113*(Age^2)+429.85*Age+252.06)/1000 ± 0.20*(0.00476622*(Age^5)-
0.27924*(Age^4)+6.3444*(Age^3)-70.113*(Age^2)+429.85*Age+252.06)/1000 [15] 
Spleen (18.42+0.018*Age*365 ± 2.5)/1000 [14] 
Stomach exp(-3.266+2.45*log(Height) ± 0.0965) [12] 
Thymus (14*((7.1-6.1*exp(-Age/11.9))*((0.14+0.86*exp(-Age/10.3))))/1000 ± 0.049 [12] 
65 
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Table 3 Equations for cardiac output and percentages of blood flow rate to each organ from the cardiac output 
adjusted according to literature data [6] 
 2-7 years 7-18 years 
Cardiac output 
60*(10^(0.8914*log10(Weight)-
0.654)) [16] 
(3.107+(0.012*Weight^1.369))*
60 [17] 
Gender → 
Organ/Tissue ↓ 
Male Female Male Female 
Adipose 0.04 0.05 0.04 0.06 
Bone 0.02 0.02 0.04 0.04 
Brain 0.38 0.38 0.24 0.24 
Gut (Qgu) 0.12 0.13 0.14 0.15 
Hepatic artery 0.08 0.08 0.06 0.07 
Kidneys 0.13 0.11 0.17 0.13 
Lungs 0.02 0.02 0.02 0.02 
Muscle 0.05 0.06 0.12 0.11 
Portal vein (Qpv) Qgu+Qst+Qsp 
Remaining 0.07 0.06 0.08 0.08 
Skin 0.03 0.03 0.04 0.04 
Spleen + Pancreas (Qsp) 0.05 0.05 0.04 0.04 
Stomach (Qst) 0.01 0.01 0.01 0.01 
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Table 4 Physicochemical properties, in vitro and population pharmacokinetic data of lorazepam and 
ceforanide 
 Lorazepam Ceforanide 
Molecular weight 321 519 
log Po:w 2.39 [9] -3.7 [18] 
Protein binding (%) 0.93 [19] 80.6 [18] 
pKa 1.3 (base), 11.5 (acid) [9] 2.55 (acid), 9.14 (base) [18] 
R 0.642 [9] †0.1173 
UGT2B7 CLint  0.439 [9] - 
Renal clearance 0.01 [9] - 
Plasma clearance - 72 ± 21 [2] 
log Po:w – Partition coefficient between octanol and water; pKa – logarithmic value of the dissociation constant; 
R – blood-to-plasma drug ratio; CLint – intrinsic clearance; UGT - uridine diphosphate glucuronosyltransferase 
(ml/min/g of liver), renal clearance is in ml/min/kg, plasma clearance is expressed in ml/min ∙ 1.73 m2; † the value 
was computed from the correlation provided by Paixão et al. [20] 
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2. Results 
The mean simulated values of the anatomy and blood flow rates of children and adolescents were compared 
against literature values [5, 6]. The validation was performed for ages 2, 5, 10 and 15 years [6]. The simulated 
paediatric characteristic values for BSA, height and weight are in agreement with literature data as shown in Table 
5. Allometric equations from various literature sources describing the organ and tissues weights and blood flow 
rates of children and adolescents are in agreement with the published data, shown in Table 6 and Table 7.  A 
separate ‘remaining’ compartment was created to accommodate the unaccounted weight (data not shown) and 
blood flow rate in order to improve the model prediction. Allometric equations for 2 years were assumed to predict 
anatomy and physiology between the ages 2 and 5 with relative accuracy and precision. Observed growth pattern 
was slightly different from 7 years onwards due to which different equations were used for allometric scaling [3].  
Due to large variation in anatomical and physiological characteristics among children and adolescents, broader 
validation range i.e. ± 100% was assumed. The mean values from the chosen allometric equations were between 
the assumed ranges from the reported literature values except for the lung weight of a 10-year-old child (101.2 
%). The mean simulated blood flow rates were ± 50% from the literature value for all the age groups (Table 7). 
. The pharmacokinetics were predicted across all age groups from 3-17 years and the mean value was 
compared with clinical data. Simulated lorazepam and ceforanide pharmacokinetics were compared against 
clinical data as shown in Table 8. For lorazepam, the Cmax, AUC and Vd were +37.5 %, +22.2 % and -14.6 % from 
clinical values [1]. Validation of intramuscular ceforanide against clinical data had a deviation of +7.4 %, +16.6 
% and -8.1 % for Cmax, AUC and Vd respectively [2]. The simulated Cmax and AUC values are slightly high which 
can be explained by the low volume of distribution observed. Due to unavailability of data, the blood-to-plasma 
ratio, fraction unbound, intrinsic and renal clearance were not altered across age groups. 
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Table 5 Validation of characteristic features against literature data for different ages (data represented as Male/Female) [5, 6] 
Years → 2 5 10 15 
Characteristic ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
BSA 0.76/0.74 NA 0.91/0.91 0.78/0.78 1.20/1.14 1.12/1.12 1.67/1.49 1.62/1.55 
Height 0.87/0.87 NA 1.09/1.09 1.09/1.09 1.39/1.37 1.38/1.38 1.80/1.53 1.67/1.61 
Weight 12.7/12.1 12.6/11.9 18.0/17.2 18.7/17.7 31.0/34.0  31.4/32.6 56.0/52.0 56.7/53.7 
 
Table 6 Validation of organ weights (kg) against literature data for different ages (Data represented as Male/Female) [5, 6] 
Years → 2 5 10 15 
Organs ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
Adipose 3.17/2.91 3.76/3.72 4.68/4.26 5.50/5.50 7.45/9.28 8.60/8.60 11.6/14.2 12.0/18.7 
Bones 0.74/0.74 0.85/0.82 2.49/2.49 2.43/2.43 4.6/4.47 4.50/4.50 8.32/8.32 7.18/7.18 
Brain 1.50/1.50 1.12/1.03 1.48/1.36 1.31/1.31 1.47/1.48 1.40/1.40 1.46/1.34 1.30/1.30 
Glands 0.02/0.02 0/0 0.06/0.06 0.04/0.04 0.07/0.07 0.06/0.06 0.06/0.06 0.10/0.10 
Heart 0.07/0.06 0.07/0.06 0.08/0.08 0.09/0.09 0.12/0.12 0.14/0.14 0.16/0.16 0.22/0.22 
Intestines 0.20/0.19 0.19/0.19 0.24/0.24 0.34/0.34 0.33/0.33 0.58/0.58 0.70/0.69 0.82/0.82 
Kidneys 0.10/0.10 0.09/0.08 0.12/0.12 0.11/0.11 0.18/0.18 0.18/0.18 0.23/0.23 0.24/0.24 
Liver 0.46/0.45 0.48/0.46 0.57/0.57 0.57/0.57 0.87/0.87 0.83/0.83 1.16/1.16 1.30/1.30 
Lungs 0.18/0.18 0.24/0.24 0.22/0.22 0.13/0.13 0.38/0.38 0.21/0.21 0.52/0.52 0.29/0.29 
Muscle 3.37/2.92 2.83/2.83 5.23/4.67 5.60/5.60 7.90/10.42 11.0/1.01 17.5/14.6 17.0/17.0 
Skin 0.52/0.49 0.41/0.39 0.64/0.62 0.57/0.57 1.65/1.65 0.82/0.82 2.19/2.19 1.70/1.70 
Spleen 0.04/0.04 0.07/0.07 0.05/0.05 0.05/0.05 0.08/0.08 0.08/0.08 0.12/0.12 0.13/0.13 
Stomach 0.03/0.03 0.03/0.03 0.05/0.05 0.05/0.05 0.09/0.09 0.09/0.09 0.16/0.11 0.12/0.12 
Thymus 0.02/0.02 NA 0.03/0.03 0.03/0.03 0.03/0.03 0.04/0.04 0.03/0.03 0.03/0.03 
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Table 7 Validation of organ blood flows (L/h) for different ages against literature values (Data represented as Male/Female) [6] 
Years → 2 5 10 15 
Organs ↓ Simulated Reference Simulated Reference Simulated Reference Simulated Reference 
Cardiac Output 
129/122 124/114 176.5/132.7 172.8/157.8 269.5/272.5 234/224.4 363.9/347.2 346.2/309 
Adipose 
5.1/4.8 5.4/5.8 7.1/8 7.2/7.8 10.8/16.4 10.8/14 14.5/20.8 13.7/25 
Brain 
41.0/38.7 54.4/50.1 63.2/32 62.7/57.8 65.6/65.8 55.5/51 46.6/42.6 45/39.9 
Gut 
11.3/10.7 13.1/12.4 24.7/19.9 23.5/22.2 37.7/40.9 35.5/35.5 50.9/52 49.7/47.7 
Hepatic Artery 
32.1/31.0 43.2/40.8 10.6/9.3 11.3/10.6 16.2/19.1 14.6/15 21.8/24.3 22.7/21.5 
Kidney 
11.9/11.3 18.5/13.3 30/17.2 22.6/16.7 45.8/35.5 42.6/30 61.8/45.1 63.2/46.8 
Lungs 
8.4/8.0 9.2/8.28 3.5/2.7 3.3/3.1 5.4/5.5 4.1/4.8 7.3/6.9 8.6/7.2 
Muscle 
1.6/1.5 2.3/2.3 13.5/14.5 13.1/13.1 31.4/29.8 25.7/25.7 57/45.8 56.2/39.8 
Remaining 
5.1/4.8 4.9/4.9 14.1/10.6 11/7.3 21.6/21.8 17.7/18.4 29.1/27.7 37/35 
Skin 
3.4/3.2 3.9/3.7 7.1/5.3 5.3/5.1 10.8/10.9 7.7/7.8 14.5/13.9 14.5/12 
Spleen 
2.6/2.4 5.0/4.6 7.1/5.3 6.4/6 10.8/10.9 8.9/9.5 14.5/13.9 15.4/13.8 
Stomach 
1.2/1.1 1.2/1.1 1.8/1.3 2/1.8 2.7/2.7 3.2/3 3.6/3.5 5/4.5 
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Table 8 Validation of lorazepam [1] and ceforanide [2] paediatric model against clinical data  
Lorazepam 
 Cmax (ng/ml) AUC (ng.h/ml) Vd (L/kg) 
Simulated 77.14 ± 15.82 1005.62 ± 268.48 1.64 ± 0.13 
Clinical 56.1 ± 44.9 822.5 ± 706.1 1.92 ± 0.84 
Ceforanide 
 Cmax (µg/ml) AUC (µg.h/ml) Vd (L/kg) 
Simulated 60.4 ± 14.4 250 ± 74.0 0.24 ± 0.16 
Clinical 56.3 ± 14.0 215 ± 61.0 0.26 ± 0.67 
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